What Is DILIN?


The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has established the Drug-Induced Liver Injury Network (DILIN) to collect and analyze cases of severe liver injury caused by prescription drugs, over-the-counter drugs, and alternative medicines, such as herbal products and supplements. Currently, DILIN is conducting 2 registry studies:

  • Retrospective Study, To establish a nationwide registry of people who have experienced liver injury within the past 10 years after using drugs or Herbal and Dietary Supplements known as HDS.
  • Prospective Study, to establish a nationwide registry of people who have experienced liver injury within the past 6 months after using certain drugs or alternative products.
  • Causality Process and Web Application, The diagnosis of drug-induced liver injury relies on evidence linking the injury to a specific drug or agent. DILIN uses “expert opinion” to determine the degree of association between the implicated medication(s) and the liver injury. This process is identified as DiLiN Causality Case Adjudication which is the DiLiN project primary Endpoint. The DiLiN Causality Web Application is a system specifically developed for this purpose. This is a secure system which was developed by the DCRI IT group for the DILIN network based on an open source platform. The Causality Web Application’s mission is to streamline the previous process which will include more efficient case management and seamless system integration to existing DILIN databases. The DiLiN Causality Web Application is also providing greater consistency within the processes by applying business rules to user’s input.

this is an image map that links to locations that are part of the DILIN network

USC/UCLA UMHS Indiana University wake forest health dcri NIDDK/NIH AEMC Mt. Sinai unc chapel hill precision medicine

Mount Sinai
UNC-chapel hill
wake health
Indiana University

Interested in participating in this study?  Contact Us

The DILIN Network Members at the Steering Committee Meeting on May 31, 2018

Bolger Center: Potomac, Maryland

Front row, L to R: Francesco Durazo (UCLA), Jawad Ahmad (Mt Sinai), Hoss Rostami (Duke), Mark Avigan (FDA), Bob Fontana (U Michigan), Jay Hoofnagle (NIDDK), Paul Watkins (UNC), Huiman Barnhart (Duke), Jose Serrano (NIDDK), Joe Odin (Mt Sinai), Vic Navarro (Einstein), Christopher Koh (NIH)

Second Row, L to R: Leonard Seeff (Einstein), Raj Vuppalanchi (Indiana U), Yi-Ju Li (Duke), Sherry Hall (NIH), Dee Faust (Wake Forest), Coleen Crespo (Duke), David Kleiner (NCI), Matt Leonard (Einstein), Naga Chalasani (Indiana U)

Third Row, L to R: Amy Huang (NIH), Paul Hayashi (UNC), Beverly Niles (NIH), Kathy Galan (Duke), Matthew Baum (Duke), Molly Prentice (Wake Forest), Andrew Stolz (USC), Wendy Morlan (Indiana U), Paola Nicoletti (Mt Sinai), Jiezhun Gu (Duke)

Fourth Row, L to R: Don Rockey (MUSC), Hans Tillmann (Eastern Carolina U), Michelle Crowder (Duke), Herb Bonkovsky (Wake Forest), Mariam Farida (U Michigan), Christine Poulsen (U Michigan), Ashley Cawthon (U Michigan), James Freston (UCONN), Stephanie Pagan (Mt Sinai), Susan Milstein (USC), Elizabeth Phillips (Vanderbilt U)


Late Breaking News

PBS Frontline “Supplements and Safety” Full Documentary 

Spike in Harm to Liver Is Tied to Dietary Aids

Fat Burning Supplement Linked to Liver Failure

Sanofi to Send Letter on Multaq Liver Failure Cases

FDA Drug Safety Communication: Severe liver injury associated with the use of dronedarone (marketed as Multaq)

Regulatory Science Update: FDA and International Serious Adverse Events Consortium Complete Third Data Release- Data focus on genetic basis of drug-induced liver injury and serious skin reaction

FDA Warns Consumers about Counterfeit Alli

FDA issues new warnings and precautions concerning diclofenac sodium, including Voltaren Gel

FDA Issues Early Communication about Ongoing Safety Review of Weight Loss Drug Orlistat